Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeting oncogene dependence and resistance.

Sunil R Hingorani1, David A Tuveson

  • 1Abramson Family Cancer Research Institute, Abramson Cancer Center of the University of Pennsylvania School of Medicine, Department of Medicine, Philadelphia 19104, USA. srhingo@mail.med.upenn.edu

Cancer Cell
|June 5, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fibroblasts: a diverse population of cells balancing homeostasis, wound healing, regeneration, inflammation, fibrosis, and cancer across organs.

JCI insight·2026
Same author

MYC-Mediated USP39 Upregulation Stabilizes SRSF1 in Pancreatic Cancer.

Molecular cancer research : MCR·2026
Same author

Brain metastasis from KRAS wild-type pancreatic cancer and organoid correlates: a case report.

Journal of gastrointestinal oncology·2026
Same author

Implantable Microdevices for In Vivo Assessment of Chemotherapy Response in Patient Derived Organoid Orthotopic Pancreatic Cancer Models.

Annals of surgery·2026
Same author

Serial Thermal Ablation Induces Abscopal Antitumor Immunity and Reveals Targetable CSF1R-Dependent Resistance in Pancreatic Cancer.

bioRxiv : the preprint server for biology·2026
Same author

Mitochondrial-Localized Keratin 17 Promotes Chemoresistance in Basal-like Pancreatic Cancer.

Cancer research·2026

Imatinib mesylate offers powerful targeted therapy but often leads to resistant cancers. Understanding resistance mechanisms is key to overcoming this challenge in oncology.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Imatinib mesylate represents a significant advancement in targeted cancer therapy.
  • Initial clinical responses to imatinib are frequently impressive across diverse malignancies.

Discussion:

  • The emergence of drug resistance is an inevitable challenge with imatinib therapy.
  • Understanding the molecular mechanisms underlying imatinib resistance is crucial.

Key Insights:

  • Several specific mechanisms of imatinib resistance have been identified.
  • These insights pave the way for strategies to overcome acquired resistance.

Outlook:

  • Further research into resistance pathways will refine targeted therapy approaches.

Related Experiment Videos

  • Developing combination therapies may enhance long-term efficacy and patient outcomes.